Article
J&J's immunology meds Stelara, Tremfya posted big revenue gains, but pricing is slipping: analyst
Rating:
0.0
Views:
73
Likes:
1
Library:
1
Johnson & Johnson touted solid growth for its immunology meds Stelara and Tremfya in its latest quarterly results, but Bernstein analysts are spotlighting steep pricing declines for the meds amid new competition.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value